C.H. Robinson Worldwide, Inc. vs Tempus AI — how do they compare? C.H. Robinson Worldwide, Inc. trades at $200.2 (market cap $23.53B), while Tempus AI trades at $58.41 (market cap $10.54B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 2.2× Tempus AI's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.26% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| CHRW | TEM | |
|---|---|---|
Market Cap | $23.53B | $10.54B |
Sector | Industrials | Broad Market / Factor |
52-Week High | $200.59 | $103.25 |
52-Week Low | $96.82 | $42.37 |
Enterprise Value | $25.02B | $11.21B |
Dividend Yield | 1.26% | — |
Signals from Pluang's Aura AI — not financial advice
CHRW trades at $196.50, up 1.55% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue declined to $16.23B in 2025, but net income margin improved to 3.7%. Recent acquisitions like DeSpir Logistics and AI-driven supply chain innovations highlight growth initiatives. Analyst consensus is mixed with a $199.38 price target, slightly above current levels.
Outlook remains cautiously optimistic given earnings momentum and operational efficiency gains, though high valuation ratios (P/E 39.78) and industry freight challenges pose risks. The stock's proximity to resistance at $199 suggests near-term consolidation potential, with long-term upside dependent on execution of tech investments and market share expansion.
Tempus AI (TEM) trades at $55.93, down 3.95% on the day, with strong analyst support (61.5% buy ratings) and a $69.20 consensus price target. The stock shows bullish technical signals with support at $55 and resistance at $58, while fundamentals reveal robust revenue growth ($1.27B in 2025) but significant losses (-$245M net income). Recent news highlights the company's expanding AI healthcare data platform and FDA approvals driving investor optimism despite ongoing profitability challenges.
TEM presents a high-risk, high-reward opportunity with Wall Street bullish on its unique healthcare data moat and AI capabilities. The primary investment thesis centers on the company's positioning to dominate precision medicine, though shareholders face substantial execution risk amid persistent losses and negative cash flow from operations. Near-term catalysts include Q2 2026 earnings on July 30 and continued expansion of high-margin data services.
Trailing returns across standard periods
Latest headlines on both assets
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →